Grant name: Late-Stage Translation of Biomedical and Behavioral Research Results in Arthritis and Musculoskeletal and Skin Diseases
Funding organization: National Institutes of Health (NIH)
Total funding amount: Up to $300,000 for Phase I and up to $2,000,000 for Phase II
Duration: Up to 1 year for Phase I and up to 3 years for Phase II
Primary objective: Support late-stage pre-clinical research and development for musculoskeletal, rheumatic, or skin diseases.
Key stakeholders: Small business concerns (SBCs), academic/non-profit labs.
Funding source: NIH.
Funding type: Grant.
Significance: Aims to enhance commercialization of research results.
Grant frequency: Recurring.
Eligible organization types: Only United States small business concerns (SBCs).
Specific qualifications: Must be organized for profit and primarily operate within the U.S.
Ownership: More than 50% owned and controlled by U.S. citizens or permanent residents.
Employee count: Not more than 500 employees.
Geographic location: Must be based in the United States.
Previous relationship with funder: Not specified.
Focus areas: Development of therapies, innovative drug delivery strategies, biomarker studies, and 3D human tissue models.
Target beneficiaries: Patients with musculoskeletal, rheumatic, or skin diseases.
Geographic coverage: United States.
Expected outcomes: Successful commercialization of new technologies.
Sustainability expectations: Not specified.
Technical expertise: Must demonstrate capability in late-stage translation of biomedical research.
Infrastructure: Not specified.
Team composition: Must include collaboration with original technology developers.
Quality standards: Emphasis on rigor and reproducibility.
Risk management: Must propose milestones for project success.
Budget range: Up to $300,000 for Phase I and up to $2,000,000 for Phase II.
Eligible costs: Total costs include direct, indirect, and fees.
Matching fund requirements: Not specified.
Payment schedule: Not specified.
Application deadlines: January 5, 2023; April 5, 2023; September 5, 2023; January 5, 2024; April 5, 2024; September 5, 2024; January 5, 2025; April 5, 2025; September 5, 2025.
Expiration date: September 6, 2025.
Must comply with NIH Grants Policy Statement.
No clinical trials allowed.
Foreign institutions are not eligible to apply.
Applications must be submitted electronically via Grants.gov.
Follow SBIR/STTR (B) Instructions in the SF424 (R&R) Application Guide.
Encourages participation from women and socially or economically disadvantaged individuals.